prikaz prve stranice dokumenta Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19
  Download
PDF 2.18 MB
master's thesis
Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19
Zagreb: University of Zagreb, School of Medicine, 2023. urn:nbn:hr:105:428032
Šušak, Frano
University of Zagreb
School of Medicine
Department of Infectious Diseases

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šušak, F. (2023). Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19 (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:428032

Šušak, Frano. "Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19." Master's thesis, University of Zagreb, School of Medicine, 2023. https://urn.nsk.hr/urn:nbn:hr:105:428032

Šušak, Frano. "Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19." Master's thesis, University of Zagreb, School of Medicine, 2023. https://urn.nsk.hr/urn:nbn:hr:105:428032

Šušak, F. (2023). 'Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19', Master's thesis, University of Zagreb, School of Medicine, accessed 03 May 2024, https://urn.nsk.hr/urn:nbn:hr:105:428032

Šušak F. Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19 [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2023 [cited 2024 May 03] Available at: https://urn.nsk.hr/urn:nbn:hr:105:428032

F. Šušak, "Utjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:105:428032

Metadata
TitleUtjecaj nealkoholne masne bolesti jetre na serumske koncentracije transformirajućeg čimbenika rasta beta u COVID-19
Title (english)The influence of non-alcoholic fatty liver disease on serum concentrations of transforming growth factor-beta in COVID-19
AuthorFrano Šušak
MentorNeven Papić (mentor)
Committee memberAdriana Vince (predsjednik povjerenstva)
Committee memberGoran Tešović (član povjerenstva)
Committee memberNeven Papić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Infectious Diseases)
Zagreb
Defense date and country2023-07-13, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract
Nealkoholna masna bolest jetre (NAFLD) vodeći je uzrok kronične jetrene bolesti u razvijenom svijetu i prepoznata je kao rizični faktor za razvoj težih oblika COVID-19. Unatoč tome, imunološki mehanizmi kojima NAFLD pogoršava COVID-19 su i dalje nepoznati. Transformirajući čimbenik rasta beta 1 (TGF-β1) sa svojim imunomodulatornim i profibrotičkim djelovanjem ima važnu ulogu u NAFLD-u. Njegova uloga u COVID-19 je manje jasna, ali bi mogla biti patofiziološka poveznica između te dvije bolesti. Cilj ovog istraživanja parova bio je analizirati serumske koncentracije TGF-β1 u COVID-19 pacijenata ovisno o prisustvu NAFLD-a i težine bolesti. U istraživanje je uključeno 60 hospitaliziranih COVID-19 pacijenata (od kojih 30 je dijagnosticiran NAFLD) i 20 zdravih kontrola (od kojih 10 je dijagnosticiran NAFLD) koji se nisu razlikovali ovisno o dobi i spolu. Izmjerene su im serumske koncentracije TGF-β1 te su hospitalizirani pacijenti dodatno podijeljeni u podskupine ovisno o težini COVID-19 (srednje teški, teški i kritični). Oboljeli od COVID-19 imali su niže vrijednosti TGF-β1 u odnosu na zdrave kontrole. Prisustvo NAFLD-a bilo je povezano s višim koncentracijama TGF-β1 i u COVID-19 oboljelih i u zdravih kontrola. Nadalje, serumske razine TGF-β1 korelirale su s težinom COVID-19, a najviše su bile u kritično bolesnih. Iako su teži oblici bolesti bili praćeni višim koncentracijama TGF-β1, u non-NAFLD skupini, za razliku od NAFLD skupine, nije postojala statistički značajna razlika u razini TGF-β1 ovisno o težini COVID-19. Osim toga, koncentracije TGF-β1 pokazale su dobru diskriminativnu vrijednost u predikciji razvoja komplikacija i loših ishoda COVID-19 poput potrebe za naprednim mjerama respiratorne potpore, vremena oporavka, primitka u jedinicu intenzivnog liječenja (JIL), razvoja nozokomijalnih infekcija i smrtnosti. Zaključno, TGF-β1 bi mogao biti dobar prognostički biomarker za težinu bolesti i loše ishode COVID-19 u pacijenata s NAFLD-om.
Abstract (english)
Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, was identified as a possible risk factor for COVID-19 severity. However, immunological mechanisms by which NAFLD exacerbates COVID-19 remain unknown. Transforming growth factor-beta1 (TGF-β1) has an important immunomodulatory and profibrotic role, which has already been well described in NAFLD. However, the role of TGF-β1 in COVID-19 remains unclear but could also be the pathophysiology link between these two conditions. The aim of this case-control study was to analyze the expression of TGF-β1 in COVID-19 patients depending on the presence of NAFLD and disease severity. Serum TGF-β1 concentrations were measured in 60 hospitalized COVID-19 patients (30 subsequently diagnosed with NAFLD) and 20 healthy controls (10 subsequently diagnosed with NAFLD). There were no differences in age and sex between the groups and the COVID-19 group was further divided into subgroups depending on disease severity (moderate, severe, and critical). The COVID-19 group had lower levels of TGF-β1 compared to healthy controls. NAFLD was associated with higher serum TGF-β1 concentrations in both the COVID-19 group and healthy controls. TGF-β1 concentrations also correlated with COVID-19 severity. However, unlike in the NAFLD group, there was no significant correlation between TGF-β1 concentrations and disease severity in the non-NAFLD group. Furthermore, admission TGF-β1 concentrations showed good discriminative accuracy in predicting the development of critical disease and COVID-19 complications (need for advanced respiratory support, ICU admission, time to recovery, development of nosocomial infections, and mortality). In conclusion, TGF-β1 could be an efficient biomarker for predicting disease severity and adverse outcomes in patients with NAFLD.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:428032
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-11-02 10:40:54